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literature on blood-based biomarkers and their potential 
value for improving the management of patients with a 
diffuse glioma. Incorporation of the study of circulating 
molecular biomarkers in clinical trials is essential for fur-
ther assessment of the potential of liquid biopsies in this 
context.
Keywords Malignant glioma · Minimally invasive 
biomarkers · Liquid biopsies · Molecular diagnostics
Introduction
Diffuse gliomas are the most frequent primary malignant 
tumors of the central nervous system [182]. Each year in 
the United States, approximately 17,000 patients are diag-
nosed with a diffuse glioma [119]. Nowadays, magnetic 
resonance (MR) imaging is the principal imaging modal-
ity for patients with suspected brain lesions [123]. For a 
definitive diagnosis of tumor type and malignancy grade, 
tumor tissue (obtained via biopsy or resection) is required 
[99]. Both low- and high-grade malignant diffuse gliomas 
Abstract Diffuse gliomas are the most common malig-
nant primary tumors of the central nervous system. Like 
other neoplasms, these gliomas release molecular infor-
mation into the circulation. Tumor-derived biomarkers 
include proteins, nucleic acids, and tumor-derived extra-
cellular vesicles that accumulate in plasma, serum, blood 
platelets, urine and/or cerebrospinal fluid. Recently, also 
circulating tumor cells have been identified in the blood 
of glioma patients. Circulating molecules, vesicles, plate-
lets, and cells may be useful as easily accessible diag-
nostic, prognostic and/or predictive biomarkers to guide 
patient management. Thereby, this approach may help 
to circumvent problems related to tumor heterogeneity 
and sampling error at the time of diagnosis. Also, liquid 
biopsies may allow for serial monitoring of treatment 
responses and of changes in the molecular characteristics 
of gliomas over time. In this review, we summarize the 
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are characterized by extensive, infiltrative growth in the 
brain parenchyma, rendering complete resection of the 
tumor impossible [36]. Even with the current standard 
treatment consisting of (combinations of) surgery, temo-
zolomide (TMZ)—or procarbazine–lomustine–vincristine 
(PCV)-based chemotherapy—and radiotherapy [159, 160], 
glioma patients still face a poor prognosis. In general, 
the median survival of low-grade glioma (LGG; WHO 
grade II) patients is 5–10 years, 3 to more than 10 years 
for WHO grade III oligodendrogliomas, 2 years for WHO 
grade III astrocytomas, and 12–18 months for WHO grade 
IV gliomas/glioblastomas [133]. Bailey and Cushing pro-
posed the first systematic and detailed classification of 
gliomas in 1926 [7]. In the course of the following dec-
ades, the morphological diagnosis (typing and grading) of 
these tumors was further refined, culminating in the most 
recent, i.e., 2007 World Health Organization (WHO) clas-
sification of diffuse gliomas [101]. Meanwhile, it is now 
fully clear that for optimal management of patients with a 
diffuse glioma more precise classification of these tumors 
is needed, and that molecular markers hold great promise 
in this respect [100, 108, 118, 170, 179, 180]. For instance, 
it has become clear that patients with grade III 1p/19q co-
deleted anaplastic oligodendrogliomas generally have a 
better prognosis than patients with other grade III glioma 
subtypes and that IDH1 mutant (secondary) glioblastomas 
tend to have a better outcome than IDH1 wild-type grade 
III astrocytomas [164].
Biomarkers are defined here as objectively measurable 
parameters that have additional (diagnostic, prognostic, 
predictive and/or monitoring) value to clinical parameters 
such as tumor type and grade, age, and performance status 
[81, 109, 133]. Detection of molecular glioma biomarkers 
such as MGMT promoter methylation, IDH1/IDH2 muta-
tion, 1p/19q co-deletion, epidermal growth factor receptor 
(EGFR) amplification and EGFR variant III (EGFRvIII) 
expression in tumor tissue is increasingly being used in 
clinical care [64, 70, 183]. For example, 1p/19q co-deletion 
in diffuse gliomas serves as a diagnostic, prognostic, and 
predictive biomarker (indicating resp. the diagnosis of oli-
godendroglioma, improved survival and improved response 
to first-line PCV chemotherapy and radiation) [166]. New 
insights into gliomagenesis [22, 121, 169] such as the poten-
tial role of glioma stem-like cells [154], intratumoral hetero-
geneity [122, 156] and molecular subtypes [125, 161, 174] 
have revealed novel potential therapeutic targets. Exam-
ples are vascular endothelial growth factor (VEGF) which 
can be targeted by the monoclonal antibody bevacizumab, 
IDH1/IDH2 mutations and the development of the specific 
inhibitor AGI-5198, and EGFRvIII with the peptide vaccine 
rindopepimut [6, 35, 57, 135]. Also, mutated IDH1 has been 
reported as a marker indicating that more radical surgical 
glioma resection may be of benefit for the patient [14].
Non-small cell lung cancer and melanoma are at the 
forefront of molecular diagnostics, with a variety of treat-
ments targeting molecular alterations defining specific can-
cer subtypes (e.g., BRAF, EGFR, ALK alterations). Accurate 
molecular diagnostics is essential for personalized therapies 
to assess patient candidacy for a particular therapy based 
on drug-sensitizing genetic alterations of the tumor. These 
specific genetic pathway alterations that are the target of a 
drug are regarded as molecular companion diagnostic bio-
markers. The FDA has issued guidelines stating that they 
will only review such targeted drugs for approval in the 
context of corresponding in vitro companion diagnostics 
[146]. Companion diagnostics for targeted cancer treat-
ments simplifies the drug discovery process, makes clini-
cal trials more efficient and informative, and can be used 
to individualize the therapy of cancer patients. There is an 
urgent need to develop molecular diagnostics to better iden-
tify the patients that respond to expensive targeted thera-
pies. Currently, mutational profiles of cancer patients are 
determined in tumor tissues. Examples are the Cobas 4800 
BRAF V600 Mutation Test (Roche Molecular Systems Inc.) 
which detects the BRAF V600E mutation in formalin-fixed, 
paraffin-embedded (FFPE) human melanoma tissue and the 
Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular 
Inc.), which detects rearrangements involving the ALK gene 
via fluorescence in situ hybridization (FISH) in FFPE tissue. 
However, limited access to serial tumor biopsies constitutes 
a major shortcoming in longitudinal molecular monitoring 
of targeted treatment. In addition, molecular diagnostics 
based on analysis of biopsied or surgically resected tumor 
tissue is hampered by sampling error. Many types of can-
cer, including melanoma, non-small cell lung cancer, and 
in particular glioma, have demonstrated to be of heteroge-
neous nature [156]. Glioma tissue heterogeneity may con-
found assessment of molecular markers such as EGFRvIII 
expression and MGMT promoter methylation. Such molecu-
lar diagnostic problems could be solved by minimally inva-
sive techniques, possibly via advanced imaging modalities 
[9, 172] or ‘liquid biopsies’ [40, 66, 72, 88, 129, 137, 155, 
168]. Additionally, liquid biopsies might allow for faster 
and more accurate tumor diagnosis of difficult-to-diagnose 
patients, e.g., patients presenting with a ring-enhancing 
lesion in the brain as measured by MR imaging that can be 
diagnosed as either a metastasized solid tumor or a primary 
brain tumor [26]. On top, molecular markers obtained via 
liquid biopsies may allow for repeated assessment of molec-
ular aberrations of the tumor and real-time treatment moni-
toring in patients with diffuse glioma.
Importantly, whereas pathologists in conjunction with 
clinical geneticists are in the midst of a transformation 
towards molecular cancer diagnostics, the field of blood-
based cancer analysis is still awaiting such a full transfor-
mation. Blood-based analysis, historically often positioned 
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at the departments of clinical chemistry and microbiology, 
may likely benefit from a repositioning within the medi-
cal disciplines involved. In practice, the optimal develop-
ment of diagnostics based on liquid biopsies—defined 
here as biofluids used for molecular diagnostics—will 
require next-level interdisciplinary action of clinical chem-
ists, clinical geneticists, microbiologists, and (molecular) 
pathologists, among others. In this review on liquid biop-
sies in patients with diffuse glioma, we provide a concise 
discussion of the current state of the art of five blood-based 
liquid biopsy biosources [plasma; serum; extracellular vesi-
cles; blood platelets (thrombocytes); circulating tumor cells 
(CTCs)], followed by a more elaborate discussion regard-
ing the potential of detecting circulating proteins, circulat-
ing nucleic acids (DNA, different forms of RNA) and of 
circulating tumor cells.
Biosources in liquid biopsies for molecular markers
Plasma and serum are collected from whole blood and 
are the most studied biosources for molecular markers 
(Fig. 1). Circulating tumor DNA (ctDNA) and microR-
NAs (miRNAs) are relatively stable in plasma and serum, 
as opposed to messenger (mRNA) that is easily degraded. 
Nevertheless, within several hours of release ctDNA is 
removed from the circulation by the liver and the kidneys 
[149]. Plasma and serum also contain extracellular vesi-
cles (EVs), which are small lipid membrane-bound satch-
els expelled by cells to mediate cell-to-cell communication 
and containing a wide collection of nucleic acids, lipids, 
and proteins [4, 43, 54, 155]. The physical structure of 
EVs protects nucleic acids from degradation by circulating 
nucleases [92, 155]. Indeed, isolation of RNA from serum-
derived EVs from patients with glioblastoma can yield a 
60× greater concentration of RNA compared to free-circu-
lating RNA from whole blood, plasma or serum [30], which 
makes EVs a promising source for circulating RNA bio-
markers. Complementary, circulating platelets are supplied 
by gliomas with tumor-derived EVs and contain tumor-
derived RNA [116]. Interestingly, the majority of EVs 
circulating in blood are also derived from platelets, sug-
gesting that platelets efficiently sequester and release EVs 
[134, 187]. Similar to EVs, internalized nucleic acids in 
Fig. 1  Overview of biomarker 
release, collection and assess-
ment. In (glial) tumors, both 
neoplastic cells and the tumor-
microenvironment release 
biomolecules in the circulation, 
either as circulating proteins 
(CP), circulating nucleic acids 
(CNA), or even complete 
circulating tumor cells (CTC). 
Blood plasma and serum are 
a source of circulating tumor 
DNA (ctDNA), circulating 
microRNAs (miRNAs) and 
circulating proteins. From 
whole blood, also extracellular 
vesicles (EVs), platelets (which 
internalize EVs) or complete 
CTCs can be isolated and used 
as potential biosources. These 
five biosources provide proteins, 
miRNAs, messenger RNAs 
(mRNA) non-coding RNAs 
(ncRNA) and ctDNA biomol-
ecules (see separate lower right 
table). Of note, in the lower 
right table only biomolecules 
that were already identified 
in the particular biosources in 
patients with diffuse glioma are 
marked. These biomolecules 
and cells can be collected from 
a routinely obtained peripheral 
blood sample and used for fur-
ther analyses in the laboratory
Glioma  
patient 
Glioma releases 
biomarkers  
into circulation 
Collection of 
Extraction of  
biomolecules 
Analysis of  
glioma biomarker  
EVs 
Platelets 
CTCs 
Biomolecules 
Protein ctDNA mRNA 
miRNA/ 
ncRNA B
io
so
ur
ce
s
Plasma 
Serum 
EVs 
Platelets 
CTCs 
Protein 
miRNA mRNA ctDNA
Nucleic acids 
x 
x 
x 
x 
x 
x 
x x 
x 
x 
x 
x 
852 Acta Neuropathol (2015) 129:849–865
1 3
platelets are protected from endogenous nucleases. Finally, 
CTCs, although widely studied for many solid tumors [87], 
were only recently detected in the blood of patients with 
glioma [104, 113, 162]. The origin of circulating biomark-
ers, either directly derived from glioma cells or indirectly 
released by cells in the tumor microenvironment, such as 
inflammatory, endothelial and stromal cells, or at more dis-
tant sites like the bone marrow, is not known for all molec-
ular biomarkers. Obviously, EGFRvIII and IDH mutant 
proteins or nucleic acids are released primarily by glioma 
cells, whereas potential biomarkers such as VEGF can be 
derived from multiple cell types. Also, both active secretion 
and passive release are possible routes for biomolecules to 
enter the circulation, e.g., via apoptotic or necrotic tumor or 
tumor-infiltrating cells [40, 149]. In this review, cerebrospi-
nal fluid (CSF) and urine are more marginally discussed as 
alternative biosources. As brain tumors are located intracra-
nially and the brain is surrounded by CSF, this fluid may be 
an additional attractive liquid biopsy biosource for glioma 
[132]. Several studies have shown the suitability of detect-
ing tumor-derived circulating nucleic acids [1, 10, 32, 132] 
and proteins [51, 53, 69, 83, 89, 90, 97, 115, 124, 142–144, 
148, 153, 189, 191, 194] in CSF. However, collecting CSF 
is a more invasive, and burdensome procedure that harbors 
risks, particularly the risk of brain herniation in subjects 
with intracranial space-occupying lesions. Biomarkers can 
be either directly released into the CSF or accumulate via 
the brain interstitial fluid and perivascular drainage system 
into the cerebrospinal fluid [23, 41, 75]. Possibly, potential 
biomarkers in CSF also end up like a ‘sink effect’ in the 
circulating blood [92].
The individual candidate biomarkers are discussed 
below in order of biomarker class, i.e., circulating proteins 
(CPs) or circulating nucleic acids (CNAs), and further sub-
classified according to biomarker type (diagnostic, prog-
nostic, predictive, monitoring). The biofluids, biosources, 
biomarker classes, and biomarker types suitable for liquid 
biopsies are summarized in Fig. 1. Moreover, we discuss 
current and future issues which may benefit from assess-
ment of circulating biomarkers and lead to improved clini-
cal care for patients with diffuse glioma.
Circulating proteins (CPs)
Under several pathological conditions including cancer, the 
secretion, shedding and/or loss of proteins can become dif-
ferentially regulated and subsequently result in increased or 
decreased levels of circulating proteins (CP) in blood, urine 
and/or CSF [17, 185]. The majority of studies concerning 
protein markers is performed on blood [number of stud-
ies (n) = 29 for plasma, and n = 40 for serum], although 
also CSF (n = 19) and urine (n = 4) have been reported 
as biosources for CPs in these patients as well. In blood-
based glioma biomarker discovery studies, proteins are so 
far the most extensively studied biomolecules (summarized 
in Supplementary Table 1). The majority of these reports is 
of an exploratory nature and most molecules have not yet 
been evaluated in large clinical trials.
Diagnostic circulating protein markers
First attempts to detect CP markers in blood of patients 
with glioma resulted predominantly in the identification 
of markers differentially expressed between patients and 
healthy controls. Plasma- and serum-derived protein mark-
ers—such as immunosuppressive acidic protein, alpha-1 
acidic glycoprotein and alpha-1 antitrypsin, the glycopro-
tein fibronectin, and the endothelial cell-derived thrombo-
modulin-1—were the first proteins to be found elevated in 
the blood of patients with glioma [84, 110, 141, 145], fol-
lowed by protein markers related to angiogenesis in glio-
mas. The serum and plasma protein levels of the marker 
VEGF have often been reported as significantly increased 
in patients with glioma compared to healthy controls [2, 28, 
37, 128, 131], and even higher in patients with metastatic 
brain lesions [71, 128]. Soluble VEGFR-1 (sVEGFR-1), 
but not sVEGFR-2, -3, and basic fibroblast growth factor 
(bFGF, alternatively known as FGF-2), have been reported 
to be increased in pre-operatively collected serum samples 
from newly diagnosed glioblastoma patients [39, 131]. 
Also, markers involved in tumor cell invasion and remod-
eling of extracellular matrix, such as matrix metalloprotein-
ases (MMPs) and tissue inhibitors of metalloproteinases 
(TIMPs), were identified as potential diagnostic CP bio-
markers. Increased levels of MMP-2 and 9 were observed 
in CSF of high-grade glioma patients [51], and a larger 
study confirmed increased plasma levels of MMP-9 and 
TIMP-1 in patients with both grade II and IV glioma com-
pared to healthy controls [95]. Surprisingly, however, in 
this study no difference was observed in the plasma protein 
levels of MMP-9 and TIMP-1 of grade III glioma patients 
as compared to healthy controls. Serum and plasma levels 
of TIMP-1 allowed the discrimination of grade IV from 
lower grade gliomas, and were confirmed in two addi-
tional studies [39, 95, 155, 157]. Furthermore, glial fibril-
lary acidic protein (GFAP) was suggested to have diagnos-
tic value [24, 68, 73, 80, 102]. An increase of circulating 
GFAP levels was observed in pre-operatively collected 
samples from grade III and IV glioma patients in both 
serum and plasma [68, 73]. Also in a subset of patients with 
oligodendroglial tumors, high levels of GFAP were found 
in plasma, implying that circulating GFAP is not specific 
for high-grade malignant astrocytic neoplasms [68]. Of 
interest, in patients with multiple sclerosis or a metastatic 
brain lesion, plasma GFAP levels were found to be within 
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the reference range [73, 102]. Plasma GFAP may, together 
with plasma placental growth factor (PlGF), differentiate 
between radiologically suspected high-grade glioma and 
brain metastases [73]. Obviously, the fact that not only 
GFAP, but also other markers such as brain-derived neuro-
trophic factor (BDNF) and S100 calcium binding protein B 
(S100B), can be detected in the circulation of healthy con-
trols negatively influences the specificity of such protein 
markers for detection of disease processes [91]. Finally, 
urine protein levels of 2-hydroxyglutarate (2-HG) may aid 
in distinguishing IDH1 mutant glioma patients from those 
with IDH1 wild-type glioma [98]. Assessment of the 2-HG 
metabolite in pre-operatively collected serum samples did 
not allow for such discrimination [27]. Potential diagnostic 
value has also been reported for serum and/or plasma lev-
els of EGFR protein [127, 151], transforming growth factor 
beta (TGFb) [147], tumor necrosis factor alpha (TNFa) [2, 
28, 59, 131], interleukin 2 (IL-2) and its receptor [59, 192], 
Chitinase-3-like protein 1 (CHI3L1, also known as YKL-
40) [15, 167], S100B [73, 102, 175], neural cell adhesion 
molecule (NCAM) [171], neuropeptide Y (NPY) [73] and 
BDNF [73].
Prognostic circulating protein biomarkers
CP markers with prognostic value can be subdivided in 
two subgroups; tumor-related markers and markers asso-
ciated with endogenous systemic stress responses. The 
glioma-related serum and plasma markers YKL-40, osteo-
pontin (OPN) and the extracellular domain of EGFR were 
described to be inversely correlated with overall survival 
[15, 63, 67, 77, 127, 157]. Interestingly, increased serum 
levels of YKL-40 1 week after surgery and during follow-
up of glioma patients, both newly diagnosed and recur-
rent, were associated with increased risk of death, also 
when adjusted for age, Karnofsky performance scale (KPS) 
and extent of surgical resection [15, 67, 77]. Furthermore, 
serum levels of YKL-40 appeared to be relatively stable 
over time [167]. In patients with recurrent glioblastoma 
prior to treatment with a combination of the monoclonal 
antibody bevacizumab and the topoisomerase 1 inhibitor 
irinotecan, elevated plasma levels of MMP-2 and decreased 
plasma levels of MMP-9 were associated with increased 
overall survival (OS) [165]. In addition, many CP mark-
ers implicated in tumor angiogenesis are associated with 
the survival of patients with glioma. The plasma levels 
of IGFBP-2 and VEGF, the serum level of plasminogen 
activator inhibitor-1 (PAI-1), and the CSF protein lev-
els of hepatocyte growth factor (HGF), bFGF and VEGF 
were inversely associated with progression-free survival 
(PFS) and OS [49, 76, 94, 124, 188]. Elevated levels of 
these CP markers may reflect more aggressive tumors 
with extensive angiogenesis and subsequent leakage of 
tumor-derived molecules into the circulation. Furthermore, 
a stress response of the body, represented by elevated lev-
els of C-reactive protein (CRP), the S100B protein, d-dimer 
and several heat shock proteins, has been associated with 
worse prognosis [65, 110, 158, 175]. Altogether, the most 
promising prognostic CP marker for glioma patients thus 
far seems to be serum YKL-40 protein.
Predictive circulating protein markers
Predictive CP markers in patients with glioma may facili-
tate therapy selection without the need for invasive tumor 
tissue biopsies. So far, predictive CP markers for patients 
with diffuse glioma were mainly identified in phase I and 
II clinical trials testing the effect of anti-angiogenic treat-
ments (esp. bevacizumab). Nevertheless, also for other 
established therapy regimens in patients with glioma, like 
TMZ treatment (see also CNAs), predictive CP mark-
ers might contribute to patient stratification. Tabouret 
et al. [165] reported that increased plasma protein levels 
of MMP-2 (>227.5 ng/ml) prior to combinatorial beva-
cizumab and irinotecan treatment were associated with 
higher probability of response to treatment (83 % com-
pared to 15 %). Decreased plasma protein levels of MMP-9 
(<235 ng/ml) were considered to be related to treatment 
response, although this was not confirmed in an additional 
patient cohort [165]. In a relatively small study (n = 10 
recurrent glioblastoma patients), Chinnaiyan et al. [34] 
identified IGFBP-5 as a possible predictive protein marker 
for combined treatment with bevacizumab, HDAC inhibi-
tor vorinostat, and irinotecan. Finally, non-responders to a 
combination therapy with bevacizumab and irinotecan had 
significantly increased plasma levels of IL-8 and G-CSF 
prior to start of the treatment as compared to responders 
[46].
Monitoring circulating protein markers
Circulating protein markers in patients with glioma that 
can be potentially employed to monitor the efficacy of a 
particular treatment are gaining attention. The individual 
biological tumor properties and complex tissue alterations 
induced by different anti-tumor treatments are not properly 
assessed with current MR imaging protocols and response 
criteria [181]. These criteria consider in particular two of 
the imaging characteristics: contrast uptake and alteration 
of the T2-weighted signal. Both characteristics, however, 
do not always properly reflect tumor behavior. Contrast 
enhancement indicates disruption of the blood–brain bar-
rier related to tumor progression, but anti-angiogenic treat-
ment reduces the number and permeability of tumor blood 
vessels and decreases the amount of MR contrast agent in 
the tumor, resulting in potential misinterpretation of tumor 
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regression (pseudo-response), whereas combined chem-
oirradiation may lead to temporarily increased contrast 
enhancement, erroneously interpreted as tumor progression 
(pseudo-progression). T2-weighted signal changes suggest 
diffuse infiltrative tumor progression, but might also be 
caused by tumor- or treatment-induced edema, resulting in 
misinterpretation as progression [163].
Blood-based biomarkers may allow circumvention of 
problematic pseudo-responses upon anti-angiogenesis 
treatment and pseudo-progression upon chemoradiother-
apy treatment. Two studies that together included approxi-
mately 90 recurrent glioblastoma patients treated with 
bevacizumab plus irinotecan demonstrated that a decreased 
plasma protein level of VEGF, measured, respectively, 
eight weeks and 15 days after the start of the treatment, 
was associated with improved PFS and OS [46, 165]. In 
addition, decreased plasma protein levels of MMP-9 were 
associated with prolonged PFS and OS, whereas changes 
in the plasma protein levels of bFGF, SDF-1a, PlGF or 
VEGFR-2 were not associated with the effect of beva-
cizumab [165]. Unfortunately, baseline levels of VEGF 
was not associated with PFS in the larger AVAglio study 
(n = 571) [139]. Treatment responses of recurrent glioblas-
toma patients (n = 26) treated with the VEGF and PlGF 
sequestering drug aflibercept were not associated with sig-
nificant changes in plasma protein levels of VEGF, despite 
initial reduction of this marker in plasma and subsequent 
increases of circulating VEGF and PlGF after 2 weeks 
of treatment [62]. Nevertheless, increased expression of 
MMP-9 and certain chemokines (e.g., MCTP3, MIF, IP-10) 
was correlated with tumor progression after 28 days of 
treatment, and may serve as putative CP monitoring mark-
ers for aflibercept treatment.
Multiple studies assessing the efficacy of the pan-
VEGFR RTK inhibitor cediranib in both newly diagnosed 
and recurrent glioblastoma patients have included circulat-
ing biomarker discovery as an important component of the 
clinical trials. CPs were assessed in plasma and urine sam-
ples at different time points during treatment. Most notably, 
in recurrent glioblastoma patients, increased plasma pro-
tein levels of PlGF and IL-8 and decreased levels of bFGF 
and sTie-2 proteins were associated with partial radiologi-
cal responses, whereas increased plasma protein levels of 
sVEGFR-1, sTie-2 and SDF-1a and decreased levels of 
PlGF correlated with radiological progression. Further-
more, a trend was observed between bFGF and SDF-1a 
levels, tumor vessel size and tumor progression. Increased 
plasma levels of PlGF and bFGF measured one day after 
start of treatment for recurrent glioblastoma correlated with 
improved OS. Increased plasma levels of MMP-2 and urine 
levels of MMP-9 measured within 1 day after the start of 
treatment were associated with shorter OS and PFS, respec-
tively [11, 13]. In a trial assessing the efficacy of cediranib 
combined with standard treatment in newly diagnosed 
glioblastoma patients, increased plasma protein levels of 
sVEGFR-1 and IL-8, after, respectively, 29 and 48 days of 
treatment, were associated with reduced PFS [12]. MMP-9 
and sVEGFR-1 were identified in plasma as potential CP 
monitoring markers for a combination therapy of TMZ plus 
the VEGF and PDGFR inhibitor vatalanib [56].
Circulating nucleic acids (CNA)
Tumor-associated CNAs have been identified in the blood 
of patients with several types of cancer as early as 1977 
[50, 93], and may be suitable for diagnosis and monitor-
ing of tumor treatment [44, 114]. Several classes of CNAs 
are detected; ctDNA including methylated DNA, mRNA, 
and small RNAs including miRNAs and transfer RNAs 
(tRNAs) (Fig. 1). Tumor-derived nucleic acids can be 
detected as cell-free entities, attached to lipid or protein 
structures, or as content of circulating EVs or blood plate-
lets [38, 40, 43, 116, 150, 155]. Of note, in a large study in 
which the presence of detectable ctDNA in several types of 
cancer was assessed only in a minority (10 %) of patients 
with glioma ctDNA was detected [16], indicating that the 
use of this biomarker in this patient category is challenging. 
In this section, we summarize the literature on CNAs in 
patients with diffuse glioma, while Supplementary Table 2 
provides a comprehensive overview of relevant studies on 
this topic.
Diagnostic circulating nucleic acid biomarkers
So far, most diagnostic CNA markers in patients with gli-
oma were detected by miRNA profiling. Circulating miR-
NAs exhibit great stability in plasma and serum [33, 111], 
and their involvement in glioma pathogenesis has been 
extensively studied [112]. Several groups reported that 
differential expression of multiple miRNA sets in plasma, 
serum and blood cells distinguishes glioma patients from 
healthy controls [74, 103, 136, 152, 178, 190]. Unfor-
tunately, the overlap between studies regarding plasma 
miRNA biomarkers is limited, and further validation is 
needed. Two studies compared the content of small RNAs 
in serum-derived EVs from patients with glioblastoma and 
healthy controls. Interestingly, RNA isolated from EVs 
appeared to be enriched for small RNAs in both healthy 
individuals and glioblastoma patients [117]. Based on the 
small RNA content, patients with glioblastoma could be 
distinguished from healthy controls [106]. Of note, it was 
recently reported that miRNAs are post-transcription-
ally modified by the enzymatic addition of nucleotides at 
the 3′-end of the mature miRNA, thereby affecting their 
release by tumor cells [86]. Hence, for miRNA biomarker 
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studies in liquid biopsies it is of crucial importance to take 
into account the presence of such non-templated nucleo-
tide additions, possibly changing the CNA biomarker 
landscape. Other serum CNA markers such as loss of het-
erozygosity (LOH) of chromosome arms 1p, 19q and 10q, 
and methylation of p16/INK4a and RASSF1A were also 
associated with the ability to identify patients with par-
ticular types of brain tumors [92, 105, 176]. Additionally, 
measurements of methylation of circulating ALU repeat 
sequences (i.e., non-coding transposable elements inte-
grated in the human genome) in plasma demonstrated a 
significant correlation with tissue methylation and were 
reported to allow for distinguishing low- from high-grade 
glioma patients and healthy controls [31].
Prognostic circulating nucleic acid biomarkers
The number of prognostic CNA biomarkers identified 
in patients with diffuse glioma so far is limited. Liu et al. 
[96] identified an association between hypermethylation of 
both MGMT and thrombospondin-1 in plasma of grade II 
and grade IV glioma patients and, counter-intuitively, an 
inferior OS. However, the authors do not provide detailed 
information on treatment regimens that may well have had 
an impact on the outcome of the included patients. In con-
trast, in a prospective study collecting longitudinal plasma 
samples from grade II–IV glioma patients, presence of 
methylated MGMT was associated with increased PFS 
and OS [48]. Finally, both increased plasma levels of miR-
454-3p and hypomethylation of ALU repeat elements in 
serum were reported to be associated with worse prognosis 
[31, 152].
Predictive circulating nucleic acid biomarkers
Predictive properties of CNA biomarkers were predomi-
nantly studied for MGMT promoter methylation, EGFRvIII 
and the IDH1 R132H mutation. In this respect, EGFRvIII 
and IDH1 R132H are regarded as companion diagnostic bio-
markers. Patients with methylated MGMT detected in serum 
ctDNA showed a significantly higher response to BCNU 
treatment, measured by imaging and clinical examination, 
compared to non-methylated MGMT ctDNA [8]. How-
ever, methylated MGMT in serum did not predict treatment 
response to the combination therapy of TMZ and cispl-
atin, possibly due to the inhibitory effect of cisplatin on the 
MGMT enzyme [8, 21, 177]. Of note, these authors demon-
strated a sensitivity of ~50–80 % and a specificity of 100 % 
of methylated MGMT in serum and plasma compared to the 
result of MGMT analysis of the tumor tissue (Supplemen-
tary Table 3). Detection of specific mutations and deletion 
variants is of interest for integration of blood-based markers 
in clinical trials, e.g., for the EGFRvIII-targeted immuno-
therapy using rindopepimut (CDX-110). Rindopepimut 
is currently being evaluated in a phase III study for newly 
diagnosed glioblastoma patients (ACT IV) and in a phase 
II study for recurrent glioblastoma patients in combination 
with GM-CSF (ReACT) [6]. Recently, EGFRvIII RNA 
has been detected in serum EVs of glioma patients [155] 
and EGFRvIII ctDNA in plasma [140]. Moreover, Nilsson 
et al. [116] documented efficient uptake of EVs by blood 
platelets and detected EGFRvIII mRNA in these elements. 
Based on this information, diagnosis of EGFRvIII through 
liquid biopsies could allow for patient selection for specific 
anti-EGFRvIII treatment during clinical follow-up and pos-
sibly also for treatment monitoring. In addition, blood-based 
diagnosis of EGFRvIII may help to circumvent the possible 
underdiagnosis of heterogeneously expressed EGFRvIII in 
tumor tissue. Another genetic event of particular interest for 
use in companion diagnostics is the IDH1 R132H mutation 
[121, 135]. Although the IDH1 mutation was detected in 
CSF EVs of glioblastoma patients, it could not be detected 
in serum EVs of the same patients [30, 32]. Boissellier et al. 
[19] detected mutant IDH1 ctDNA with a sensitivity of 
60 % and a specificity of 100 %. In this study, detection of 
mutant IDH1 in LGG patients depended on tumor volume 
and in high-grade glioma patients on the presence of con-
trast enhancement as visualized by MR imaging.
Monitoring circulating nucleic acid biomarkers
EGFRvIII ctDNA, or EGFRvIII mRNA in EVs or platelets 
may be considered as a monitoring marker in studies of 
therapeutics specifically or indirectly targeting EGFRvIII. 
The loss of ctDNA EGFRvIII was noted in two patients 
following gross total resection of the tumor [140]. Fur-
thermore, assessment of the MGMT methylation status in 
blood during TMZ treatment revealed that the cumulative 
incidence of unmethylated MGMT promoter, measured in 
longitudinal samples from 58 patients with diffuse glioma, 
increased from 58 % at the start of TMZ treatment to 92 % 
after 12 months of follow-up. This may be explained by the 
selection and outgrowth of tumor subclones with unmethyl-
ated MGMT promoter during TMZ treatment [48]. Circu-
lating miRNA markers, which raised to reference levels of 
healthy controls following surgery and radio-chemotherapy 
of patients with diffuse glioma, may also have monitor-
ing value [178, 190]. Furthermore, the significantly higher 
levels of miR-23, -150, -197 and -548b-5p were reported 
to occur in serum of patients with radiation necrosis/astro-
gliosis (n = 11) rather than in patients with diffuse glioma 
and may be of value to distinguish tumor progression from 
pseudo-progression after radiation (AUC: 0.95 95 % CI 
0.902–0.998) [190].
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Circulating tumor cells (CTCs)
Circulating tumor cells are neoplastic cells that are detected 
in the circulation, and that can potentially be used as bio-
marker biosource [120]. CTCs are isolated through sophis-
ticated techniques that separate CTCs from other blood 
cells by their unique physical and biological properties 
[3]. While previous attempts to isolate glioma CTCs were 
unsuccessful [18, 107], three independent research groups 
recently reported isolation of CTCs from glioma patients 
using three different novel isolation and detection methods 
(see also Supplemental Table 2). First, fluorescence immu-
nocytochemistry was performed on purified mononuclear 
cells for GFAP-positive, CD45-negative CTCs. In 28 out 
of 141 glioblastoma patients, CTCs were identified, while 
these CTCs were not detected in patients with brain metas-
tases. Following surgery, no significant difference was 
observed in CTC counts before, during or after surgery and 
no correlation between CTC counts and clinical outcome 
was found [113]. Second, a telomerase-responsive adeno-
viral vector encoding a fluorescent reporter was employed 
to detect hTERT-positive cells, resulting in detection of 
CTCs in 8 out of 11 glioblastoma patients analyzed before 
radiotherapy and TMZ treatment. In two patients, the 
quantitation of CTCs allowed the separation of pseudo-
progression from tumor progression as measured by MR 
imaging [104]. Finally, Sullivan et al. applied a CTC-iChip, 
which allows the removal of anucleated cells and depletion 
of leukocytes from the remaining cell pellet via magneti-
cally tagged antibodies (CD16, CD45), yielding untagged 
and un-manipulated CTCs. Next, fluorescent probes target-
ing five markers for glioma cells (termed STEAM: Sox2, 
Tubulin beta-3, EGFR, A2B5, c-Met) were introduced. In 
13 out of 33 glioblastoma patients, CTCs were detected. 
CTCs were enriched for transcripts associated with a mes-
enchymal glioblastoma signature. Interestingly, the expres-
sion levels of these transcripts were not always in accord-
ance with the signature that was detected in the tissue of 
the corresponding glial tumor, suggesting a preference of 
a particular subset of tumor cells (not necessarily being the 
predominant tumor cell population) for entering the circu-
lation. Moreover, no additional correlations between CTCs 
and clinical parameters were observed [162]. Of note, a 
potential role for circulating endothelial (precursor) cells 
and T-lymphocytes (esp. T-regulatory cells) as diagnostic, 
prognostic, predictive, and monitoring markers in patients 
with diffuse glioma has been suggested [5, 13, 37, 42, 
47, 60, 61, 128, 130, 184, 193]. In addition, immune cells 
release a broad range of CPs that could be of interest in 
this respect. The diagnostic value of immune cell-derived 
CNAs remains to be investigated [187]. In conclusion, suc-
cessful isolation of CTCs from the blood of glioma patients 
was demonstrated using different techniques. In 20–73 % 
of high-grade glioma patients CTCs were detected. It 
remains to be evaluated whether glioma CTCs fully repre-
sent the heterogeneous tumor cell population, and what the 
diagnostic, prognostic, predictive and monitoring potential 
of CTCs is in patients with diffuse gliomas.
Conclusions and future directions
Biomarkers can be isolated from biofluids such as blood, 
and also CSF and urine. There is a plethora of small and 
mainly explorative studies describing blood-based bio-
markers in patients with diffuse glioma. The use of different 
techniques and methodologies for detection of the biomark-
ers and the mainly retrospective nature of the studies com-
plicates drawing solid conclusions. In Fig. 2, we provide an 
overview of the biomarkers in liquid biopsies reported to 
be of potential relevance for diagnosis and/or management 
of patients with diffuse glioma. All blood-based biomarkers 
reported until now need further validation. Meanwhile, in 
the near future assessment of blood-based biomarkers can 
be expected to improve patient stratification and monitor-
ing. Ideally, phase I trials should already include biomarker 
discovery, with further validation of potential biomarkers 
in phase II and III trials, including determination of proper 
cutoff values for biomarkers [77]. Furthermore, additional 
studies are needed that uncover potential circulating bio-
markers accompanying MR imaging during clinical follow-
up for, e.g., LGG patients. Finally, markers suggested in 
this review such as PlGF and GFAP have to be evaluated 
for its diagnostic potential for difficult-to-diagnose patients 
(e.g., in the differential diagnosis of metastasis versus pri-
mary brain tumor). The evaluation of biomarker panels 
[39, 45, 151], instead of sole biomarkers, using standard-
ized detection methods, could be useful for further enhanc-
ing the sensitivity and specificity of blood tests [167]. This 
could be accompanied by a two or more steps decision 
tree algorithm as was recently shown for three diagnostic 
CP markers (GFAP, IGFBP-2, and YKL-40) [52]. The use 
of “omic-approaches” is likely to boost such a biomarker 
panel analysis [20, 55, 82, 83, 89, 97, 115, 148, 194].
The most extensively studied CP biomarkers are circu-
lating angiogenesis-related proteins. While such proteins 
may indeed be useful as prognostic and monitoring bio-
markers for anti-angiogenic therapies, a robust biomarker 
for the monitoring of bevacizumab treatment (i.e., the most 
widely applied anti-angiogenic therapy to date) has not yet 
been reported. Additionally, the discovery of tumor-derived 
ctDNA, circulating miRNAs, EVs and platelets sequester-
ing tumor-derived EGFRvIII do point at the possibility 
to use blood as a source of CNA biomarkers in patients 
with diffuse glioma. An advantage of CNA biomarkers is 
the possibility to detect genetic aberrations such as IDH1 
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mutations and EGFRvIII, which are of special interest as 
predictive markers for current clinical trials. Acknowledg-
ing that ctDNA so far was measurable in only a minority 
of patients with a diffuse glioma, detection of RNA might 
be more sensitive as compared to ctDNA, especially when 
analyzing the fraction of EVs or blood platelet in which 
RNAs are protected from circulating nucleases [16]. 
Assessment of circulating biomarkers may be of particular 
value for molecular markers that are known to be heteroge-
neously distributed (with a danger of sampling error) such 
as EGFRvIII. Also, IDH1 mutations detected in ctDNA and 
EVs isolated from CSF may provide a way for non-invasive 
assessment of diagnostic and prognostic properties.
Thus far, many different tumor-related and tumor-
derived markers have been identified in the circulation of 
patients with glioma that might attribute as specific bio-
markers. Rational selection of the most promising biomark-
ers for incorporation in clinical trials is warranted, with 
literature mining as an important tool for such a selection. 
Potential biomarkers extracted from the present review of 
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Fig. 2  Example of molecular biomarker assessment using liquid 
biopsy in patients with low- and high-grade glioma. Central black 
line depicts a simplified timeline of clinical events for patients with 
low- or high-grade glioma (LGG versus HGG). A pre-surgical work-
ing diagnosis (based on esp. clinical and radiological investiga-
tions) leads to surgery (biopsy or resection of tumor tissue). After a 
pathological diagnosis is made, most glioma patients receive ‘con-
ventional chemo- and/or radiotherapy’ (CCR), but in LGG patients 
clinical monitoring is also (still) common practice. Especially after 
failure of CCR, experimental therapy (ET) can be administered. 
Above the timeline, imaging (available during the entire follow-up 
of the patient) and the most widely accepted molecular biomarkers 
analyzed in diffuse glioma tissue samples are depicted. Tumor tissue 
samples are obtained during surgery, and might again be obtained at 
the moment of tumor progression (dashed line box). The boxes below 
the timeline show promising blood-based biomarkers as deduced 
from this review and grouped according to their potential meaning 
(diagnostic, prognostic, predictive, monitoring) in different phases 
of the disease process. The blood-based biomarkers mentioned here 
are selected based on the number of studies measuring the biomarker 
and the number of patients included in these studies. Each charac-
ter indicates for which group of diffuse glioma patients or treatment 
the biomarker might be suitable. #Predictive and monitoring markers 
selected for CCR regimens (temozolomide and procarbazine–lomus-
tine–vincristine treatment). §Predictive and monitoring markers 
selected for experimental therapies (see also individual characters). 
Characters accompanying biomarkers: a primary GBM (pGBM) 
vs. healthy controls, b pGBM vs. LGG, c LGG vs. healthy control, 
d secondary GBM vs pGBM, e primary diffuse glioma vs. metas-
tasis to the brain, f HGG, g LGG, h surgery, i temozolomide treat-
ment, j chemoradiotherapy, k bevacizumab and irinotecan treatment, 
l cediranib treatment, m aflibercept treatment, n rindopepimut (anti-
EGFRvIII) treatment, o IDH1 mutant inhibitor AGI-5198
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the literature for different stages of clinical management 
of patients with diffuse gliomas are summarized in Fig. 2. 
Obviously, regular and systematic evaluation of promis-
ing blood-based biomarkers, preferable on an international 
level via research communities such as the EORTC, would 
improve the assessment of their clinical value. Systematic 
collection of blood samples for future biomarker discov-
ery and the establishment of blood biobanks, also outside 
clinical trails, would be very helpful in this respect. Ide-
ally, such samples would be collected both prior to treat-
ment (to allow for identification of diagnostic, prognostic 
and predictive biomarkers) as well as during therapy, the 
latter in particular situations in which robust predictive and 
monitoring biomarkers are still lacking (e.g., bevacizumab 
treatment).
Blood-based liquid biopsies are of interest for the longi-
tudinal monitoring of tumor activity and therapy response. 
Depending on the blood fraction (i.e., serum or plasma), 
levels of CPs, CNAs, and possibly CTCs may vary consid-
erably. Some markers have demonstrated biomarker value 
in plasma, whereas others were only of potential value in 
serum [188]. Also, used assays and methodologies for 
detection of CPs, (modified) CNAs and CTCs, each with its 
own strengths and weaknesses, have to be critically consid-
ered, and standardization is required to be able to compare 
results between studies. Furthermore, storage conditions 
of liquid biopsy samples require consideration, as well as 
other variables such as disease state, histological tumor 
subtype, time of sampling, biosource and biomarker iso-
lation procedures, treatment regimen, assay reproducibil-
ity and sensitivity, protein half-life, biological processes, 
and normalization standards [25, 29, 39, 58, 73, 78, 79, 
138, 147, 153, 173, 186, 195]. Of note, the sequestration 
of several proteins and nucleic acids in platelets and the 
potential release of proteins and nucleic acids by platelets 
and immune cells during surgery and blood processing 
have to be taken into account [39, 85, 147]. Therefore, to 
thoroughly address these issues and to control for them, 
large standardized clinical studies, requiring specific study 
designs and well-validated molecular assays, will be of 
critical importance. Importantly, proper selection of a con-
trol group with a disease that is a meaningful differential 
diagnosis for glioma patients (e.g., tumor metastasis to the 
brain, primary CNS lymphoma, or infection) is important, 
especially in biomarker discovery [52, 126]. Conventional 
biomarker discovery using state-of-the-art next-generation 
DNA/RNA sequencing or protein quantifications can be 
expected to yield novel biomarkers correlated to a specific 
disease state.
In conclusion, the interest in liquid biopsies for the diag-
nostics of glioma is rapidly expanding. In recent years, 
many circulating biomarkers have been detected, evaluated 
and integrated in clinical trials. In the coming years, more 
large-scale biomarker discovery efforts in patients with dif-
fuse gliomas can be expected. Advances in the development 
of more sensitive assays allow for detection of low abundant 
(mutant) biomolecules in the circulation, further expanding 
the width of assessable biomarkers. Selection and validation 
of potential circulating biomarkers for patients with diffuse 
glioma is warranted. In the future, blood-based companion 
diagnostics may improve the drug discovery process for dif-
fuse glioma patients and further individualize the therapy 
of these patients. Within the coming decade, the ongoing 
research may well result in an interdisciplinary transforma-
tion of the classical blood-based analyses towards the rou-
tine use of liquid biopsies for molecular diagnostics, simi-
larly as we observed for tissue biopsies.
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